BusinessActinium Pharmaceuticals Provides Update on Pivotal Phase 3 Trial of Iomab-B: Independent Data Monitoring Committee Recommends SIERRA Trial ContinueBy Nasdaq OMXDec 27, 2017, 2:00 PM UTC
BusinessActinium Pharmaceuticals Unveils Actimab-MDS and Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic MutationsBy Nasdaq OMXDec 5, 2017, 12:30 PM UTC
BusinessActinium Pharmaceuticals Announces Multiple Posters/Abstracts Accepted for 59th Annual American Society of Hematology Meeting Highlighting Company’s Drug Candidates and Technology PlatformBy Nasdaq OMXNov 1, 2017, 1:05 PM UTC
BusinessActinium Pharmaceuticals Announces Activation of Fifteenth Clinical Trial Site in the Phase 3 SIERRA Trial for Iomab-BBy Nasdaq OMXOct 25, 2017, 11:30 AM UTC
BusinessActinium Pharmaceuticals to Present at BIO Investor ForumBy Nasdaq OMXOct 16, 2017, 11:30 AM UTC
BusinessActinium Pharmaceuticals Provides Update on Actimab-A Phase 2 Clinical Trial for Patients with Acute Myeloid LeukemiaBy Nasdaq OMXOct 4, 2017, 11:30 AM UTC
BusinessActinium Pharmaceuticals to Participate in American Society for Blood and Marrow Transplantation 2017 Corporate Council MeetingBy Nasdaq OMXSep 20, 2017, 11:30 AM UTC
